Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Randall J BatemanJanice SmithMichael C DonohuePaul DelmarRachid AbbasStephen SallowayJakub WojtowiczKaj BlennowTobias BittnerSandra E BlackGregory KleinMercè BoadaTimo GrimmerAkira TamaokaRichard J PerryR Scott TurnerDavid WatsonMichael WoodwardAngeliki ThanasopoulouChristopher LaneMonika BaudlerNick C FoxJeffrey L CummingsPaulo FontouraRachelle S Doodynull nullPublished in: The New England journal of medicine (2023)
Among persons with early Alzheimer's disease, the use of gantenerumab led to a lower amyloid plaque burden than placebo at 116 weeks but was not associated with slower clinical decline. (Funded by F. Hoffmann-La Roche; GRADUATE I and II ClinicalTrials.gov numbers, NCT03444870 and NCT03443973, respectively.).